Month: July 2019

Risk-Based Monitoring Improved

On July 17th, the FDA and Duke Margolis Center for Health Policy sponsored a workshop entitled “Improving the Implementation of Risk-Based Monitoring Approaches of Clinical Investigations”. The sessions featured 24 speakers representing the FDA, EMA, large pharma, CROs/AROs, clinical vendors, TransCelerate, MCC, SCRS, and SCDM.

Read More »